BackASLAN Pharmaceuticals Overview

ASLAN Pharmaceuticals Total Current Liabilities

Latest total current liabilities for ASLN: $20M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$19.60M
15.65% YoYΔ $-3.64M vs prior year quarter

Peer average

Loading

ASLAN Pharmaceuticals Total Current Liabilities History

Loading

ASLAN Pharmaceuticals vs. peers: Total Current Liabilities Comparison

Loading

ASLAN Pharmaceuticals Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ASLAN Pharmaceuticals (ASLN) FAQ

ASLAN Pharmaceuticals (ASLN) currently reports a total current liabilities of $20M as of March 2024. That compares with $23M in the prior-year period — down 15.6% year over year. Use the charts on this page to explore ASLAN Pharmaceuticals's total current liabilities history and peer comparisons.

ASLAN Pharmaceuticals's total current liabilities decreased from $23M to $20M — a 15.6% year-over-year decrease (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ASLAN Pharmaceuticals reported $20M in total current liabilities as of March 2024. That compares with $23M in the prior-year period — down 15.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ASLAN Pharmaceuticals, and consider following ASLN for alerts when major investors trade the stock.

ASLAN Pharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ASLN with unrelated industries.